Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with Carboplatin/BBBD in Recurrent PCNSL
NCT00074165Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2003
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in primary central nervous system lymphoma (PCNSL), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 years. Started Jan 2003; status: terminated.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00074165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074165.